NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Oxford Blood Group
    • Case Studies
    • PPIE Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Musculoskeletal > BRC funds study to test anti-TNF drugs on post-operative delirium

BRC funds study to test anti-TNF drugs on post-operative delirium

27 July 2022 · Listed under Musculoskeletal, Preventive Neurology

University of Oxford researchers have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent delirium following surgical operations.

Shutterstock.com

Post-operative delirium is an important problem, recognised as the most common surgical complication in older adults, occurring after many types of surgery. According to UK national audit data, 25 per cent of all hip fracture patients develop post-operative delirium. Hip fracture patients who develop delirium are twice as likely to die while in hospital and nearly four times more likely to require nursing home care compared with those who do not have delirium.

Patients who develop delirium are approximately four times more likely to develop cognitive memory deficit over three years, increasing to eight times higher likelihood over eight years. Every year, there are around 70,000 hip fractures in the UK and 300,000 in the US.

A team from the University of Oxford has found that the trauma associated with surgery leads to the release of proinflammatory mediators, especially TNF, which in turn leads to inflammation of a part of the brain called the hippocampus. The hippocampus is involved in memory and associated with learning and emotions.

The new trial, which will explore whether TNF therapy can reduce or prevent post-operative delirium and cognitive deficit, will be led by Professor Matt Costa of the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS).

Prof Costa (pictured left), Co-theme Lead for the NIHR Oxford Biomedical Research Centre (BRC) Musculoskeletal Theme, said: “Delirium is a terrible condition where patients get very confused and forget where and even who they are. It’s very distressing for the patients but also for their relatives.

“While most patients recover in the days after surgery, we now know that some patients with delirium develop permanent symptoms. This new trial is very exciting. If we can reduce the severity of delirium after surgery, we should be able to improve the long-term quality of life for this important group of patients.”

The study, designed as a multi-centre, randomised placebo-controlled trial in patients with hip fracture aged 60 years and above, is expected to be open for enrolment in the first half of 2023. As well as the NIHR, it is funded by 180 Life Sciences, a clinical stage biotech company.

“This is a major achievement by the team,” said Dr Jim Woody, CEO of 180 Life Sciences. “This dual funding model and collaboration between academia and industry leverages the expertise of both to develop new therapeutic strategies, for what we believe is a major unmet medical need, in the most effective way to benefit patients in the shortest possible timescale.”

← Gene variant links trigger finger and carpal tunnel syndrome
£1.2m award to improve diagnosis of emergency spinal condition →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre